Bleakley Financial Group
ESPR icon

Bleakley Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Bleakley Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,357
Closed -$36K – 653
2024
Q4 		$36K Hold
16,357
– – ﹤0.01% 1031
2024
Q3 		$27K Sell
16,357
-38
-0.2% -$77 ﹤0.01% 1014
2024
Q2 		$36.4K Hold
16,395
– – ﹤0.01% 993
2024
Q1 		$43.9K Sell
16,395
-8,003
-33% -$19.4K ﹤0.01% 974
2023
Q4 		$73K Sell
24,398
-6,104
-20% -$7.92K ﹤0.01% 909
2023
Q3 		$29.9K Buy
+30,502
New +$44.1K ﹤0.01% 865
2023
Q2 		– Sell
-11,092
Closed -$17.6K – 938
2023
Q1 		$17.6K Sell
11,092
-191
-2% -$986 ﹤0.01% 900
2022
Q4 		$70.3K Buy
+11,283
New +$80.7K ﹤0.01% 832

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bleakley Financial Group's ESPR Position: Q1 2025 in Review

Bleakley Financial Group sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 16,357 shares — an estimated $36K sold.

Bleakley Financial Group first reported a position in ESPR in Q4 2022 and held it in 8 quarters. The position peaked at $73K in Q4 2023. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Bleakley Financial Group reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 16,357 Esperion Therapeutics shares in Q1 2025, an estimated $36K.
  • Bleakley Financial Group first reported a position in Esperion Therapeutics in Q4 2022 and held it in 8 quarters.
  • Bleakley Financial Group's Esperion Therapeutics position peaked at $73K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.